European Market Infrastructure Regulation

Morgan Stanley First Quarter 2023 Earnings Results

Retrieved on: 
Wednesday, April 19, 2023

ESMA finds data quality significantly improves under new monitoring approach

Key Points: 

<span class="field field--name-title field--type-string field--label-hidden">ESMA finds data quality significantly improves under new monitoring approach </span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span>iris.hude@esma…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">19 April 2023</span>

  &lt;div class=&quot;field field--name-field-news-section field--type-entity-reference field--label-hidden field__items&quot;&gt;
          &lt;div class=&quot;field__item&quot;&gt;&lt;a href=&quot;https://www.esma.europa.eu/press-news/esma-news?tid%5B0%5D=6206&quot; hreflang=&quot;en&quot;&gt;Market data&lt;/a&gt;&lt;/div&gt;
      &lt;/div&gt;

        &lt;div class=&quot;clearfix text-formatted field field--name-field-news-introduction field--type-text-long field--label-hidden field__item&quot;&gt;&lt;p&gt;The European Securities and Markets Authority (ESMA), the EU’s financial markets regulator and supervisor, today published the &lt;a href=&quot;https://www.esma.europa.eu/sites/default/files/2023-04/ESMA74-427-719_2022_Report_on_Quality_and_Use_of_Transaction_Data.pdf&quot;&gt;third edition of its Data Quality Report&lt;/a&gt; under the European Markets Infrastructure Regulation (EMIR) and the Securitised Financing Transactions Regulation (SFTR) reporting regimes. &lt;/p&gt;

</div>

        &lt;div class=&quot;clearfix text-formatted field field--name-field-news-body field--type-text-long field--label-hidden field__item&quot;&gt;&lt;p&gt;The report highlights the increased use of transaction data by EU financial regulatory authorities in their day-to-day supervision and identifies significant quality improvements following a new approach to data monitoring. In addition, it sets out how ESMA, together with the National Competent Authorities (NCAs), the European Central Bank (ECB) and the European Systemic Risk Board (ESRB), has incorporated key insights from its data monitoring in several internal workstreams. &lt;/p&gt;

<p>The new framework, adopted in 2022, takes a more data-driven and outcome-focused approach to data monitoring and to collaborating with the NCAs on data quality issues under EMIR and SFTR. </p>
<p>Specifically, it consists of two new elements: </p>
<ul><li>a centralised data quality dashboard with EU-wide indicators covering the most fundamental data quality aspects under EMIR;</li>
<li>a data sharing framework that enables relevant authorities to follow up with counterparties when potentially significant data quality issues are detected  </li>
</ul><p>New this year is the analysis of MiFiR transaction data from Authorized Reporting Mechanisms (ARMs) and Approved Publication Arrangements (APAs), following on from ESMA’s new supervisory powers over Data Reporting Services Providers (DRSPs).  </p>
<p>The methodology underlying the new approach is based on ESMA’s long-standing experience as supervisor of Trade Repositories (TRs) under EMIR and SFTR.</p>
<h4>Next steps   </h4>
<p>ESMA and the NCAs will continue to work on extending the new monitoring framework beyond EMIR and SFTR in 2023.  </p>
<p>Continued collaboration with NCAs and stakeholders such as Repositories, DRSPs and reporting entities is crucial to achieving further improvements to data quality under the relevant reporting regimes.</p>
<p> </p>
<p>Further information:</p>
<h6>Sarah Edwards</h6>
<p>Senior Communications Officer<br />
@ <a href="mailto:[email protected]">press@esma.europa.eu</a></p>
</div>

  &lt;div class=&quot;field field--name-field-news-document field--type-entity-reference field--label-hidden field__items&quot;&gt;
          &lt;div class=&quot;field__item&quot;&gt;

<tr><td headers="view-created-table-column" class="views-field views-field-created">
19/04/2023
</td>
<td headers="view-field-document-reference-table-column" class="views-field views-field-field-document-reference">

        &lt;div class=&quot;field field--name-field-document-reference field--type-string field--label-hidden field__item&quot;&gt;ESMA74-427-719&lt;/div&gt;

    &lt;/td&gt;

<td headers="view-title-table-column" class="views-field views-field-title">
<a href="https://www.esma.europa.eu/document/2022-report-quality-and-use-transact... rel="bookmark"><span class="field field--name-title field--type-string field--label-hidden">2022 Report on Quality and Use of Transaction Data</span>
</a>
</td>
<td class="views-field views-field-nothing">
<span class="download-single-button">
<a href="https://www.esma.europa.eu/sites/default/files/2023-04/ESMA74-427-719_20... rel="bookmark" download=""></a>
</span>
</td>
<td class="views-field views-field-field-main-document">
<input type="checkbox" class="filesToDownloadInZip" data-value="file:201246" /><label></label>
</td>
</tr></div>
</div>

        &lt;div class=&quot;field field--name-field-news-hearing field--type-entity-reference field--label-hidden field__item&quot;&gt;&lt;a href=&quot;https://www.esma.europa.eu/press-news/hearings/webinar-2022-esma-data-quality-report&quot; hreflang=&quot;en&quot;&gt;Webinar on the 2022 ESMA Data Quality Report&lt;/a&gt;&lt;/div&gt;

ESMA finds data quality significantly improves under new monitoring approach

Retrieved on: 
Wednesday, April 19, 2023

ESMA finds data quality significantly improves under new monitoring approach

Key Points: 
  • ESMA finds data quality significantly improves under new monitoring approach
    The European Securities and Markets Authority (ESMA), the EU’s financial markets regulator and supervisor, today published the third edition of its Data Quality Report under the European Markets Infrastructure Regulation (EMIR) and the Securitised Financing Transactions Regulation (SFTR) reporting regimes.
  • The report highlights the increased use of transaction data by EU financial regulatory authorities in their day-to-day supervision and identifies significant quality improvements following a new approach to data monitoring.
  • The new framework, adopted in 2022, takes a more data-driven and outcome-focused approach to data monitoring and to collaborating with the NCAs on data quality issues under EMIR and SFTR.
  • Specifically, it consists of two new elements:
    - a centralised data quality dashboard with EU-wide indicators covering the most fundamental data quality aspects under EMIR;
    - a data sharing framework that enables relevant authorities to follow up with counterparties when potentially significant data quality issues are detected
    New this year is the analysis of MiFiR transaction data from Authorized Reporting Mechanisms (ARMs) and Approved Publication Arrangements (APAs), following on from ESMA’s new supervisory powers over Data Reporting Services Providers (DRSPs).

Traders Union analysts named the best CySEC regulated brokers

Retrieved on: 
Saturday, February 11, 2023

LIMASSOL, Cyprus, Feb. 11, 2023 /PRNewswire-PRWeb/ -- Cyprus is one of the most popular jurisdictions for registration of Forex brokers, with a wide choice of companies registered in the country. Traders need to choose the right company to meet their needs and expectations. Traders Union experts compiled a rating of the Best CySEC regulated Brokers, selecting brokers with the best trading conditions.

Key Points: 
  • Traders Union experts compiled a rating of the Best CySEC regulated Brokers.
  • Traders Union experts compiled a rating of the Best CySEC regulated Brokers , selecting brokers with the best trading conditions.
  • Best brokers licensed by CySECWhile selecting CySEC licensed brokers to include in the rating, Traders Union analysts reviewed choice of assets, fees, passive income options, deposit and withdrawal methods of brokers and other criteria.
  • TU experts included the following companies in list of the best CySEC regulated brokers:

Cboe Clear Europe Receives Permanent Recognition as a non-UK Central Counterparty

Retrieved on: 
Thursday, January 12, 2023

AMSTERDAM and LONDON, Jan. 12, 2023 /PRNewswire/ -- Cboe Global Markets Inc. (Cboe: CBOE), a leading provider of global market infrastructure and tradable products, today announced that Cboe Clear Europe, its Amsterdam-based clearing house, has received permanent recognition by the Bank of England to operate as a central counterparty (CCP) in the UK.

Key Points: 
  • AMSTERDAM and LONDON, Jan. 12, 2023 /PRNewswire/ -- Cboe Global Markets Inc. (Cboe: CBOE), a leading provider of global market infrastructure and tradable products, today announced that Cboe Clear Europe, its Amsterdam-based clearing house, has received permanent recognition by the Bank of England to operate as a central counterparty (CCP) in the UK.
  • Arnoud Siegmann, Interim President and Chief Operating Officer, Cboe Clear Europe, said: "We are delighted to announce the removal of Brexit uncertainty for UK-based clearing members and UK trading venues that wish to continue to access Cboe Clear Europe and benefit from its services on a permanent basis.
  • Cboe Clear Europe, which is an EU-authorised CCP under the European Market Infrastructure Regulation (EMIR), is the first non-UK CCP to achieve permanent recognition by the Bank of England.
  • Cboe Clear Europe operates as an independent subsidiary of the Cboe group, retaining a separate governance structure and management team.

Cboe Clear Europe Receives Permanent Recognition as a non-UK Central Counterparty

Retrieved on: 
Thursday, January 12, 2023

AMSTERDAM and LONDON, Jan. 12, 2023 /PRNewswire/ -- Cboe Global Markets Inc. (Cboe: CBOE), a leading provider of global market infrastructure and tradable products, today announced that Cboe Clear Europe, its Amsterdam-based clearing house, has received permanent recognition by the Bank of England to operate as a central counterparty (CCP) in the UK.

Key Points: 
  • AMSTERDAM and LONDON, Jan. 12, 2023 /PRNewswire/ -- Cboe Global Markets Inc. (Cboe: CBOE), a leading provider of global market infrastructure and tradable products, today announced that Cboe Clear Europe, its Amsterdam-based clearing house, has received permanent recognition by the Bank of England to operate as a central counterparty (CCP) in the UK.
  • Arnoud Siegmann, Interim President and Chief Operating Officer, Cboe Clear Europe, said: "We are delighted to announce the removal of Brexit uncertainty for UK-based clearing members and UK trading venues that wish to continue to access Cboe Clear Europe and benefit from its services on a permanent basis.
  • Cboe Clear Europe, which is an EU-authorised CCP under the European Market Infrastructure Regulation (EMIR), is the first non-UK CCP to achieve permanent recognition by the Bank of England.
  • Cboe Clear Europe operates as an independent subsidiary of the Cboe group, retaining a separate governance structure and management team.

New S&P Global Market Intelligence global survey finds stark contrast between European and US financial regulation readiness

Retrieved on: 
Tuesday, November 15, 2022

NEW YORK, Nov. 15, 2022 /PRNewswire/ -- While the importance of global regulatory reporting continues to increase, there is a noticeable contrast between readiness across geographies, according to the S&P Global Market Intelligence Global Regulatory Reporting Survey, published today.

Key Points: 
  • NEW YORK, Nov. 15, 2022 /PRNewswire/ -- While the importance of global regulatory reporting continues to increase, there is a noticeable contrast between readiness across geographies, according to the S&P Global Market Intelligence Global Regulatory Reporting Survey, published today.
  • "The survey results indicate that more than a year ahead of implementation, those firms with EMIR Refit reporting requirements are taking a proactive approach to regulatory readiness," said Igor Kaplun, Head of Cappitech Business Development, S&P Global Market Intelligence.
  • Conducted by S&P Global Market Intelligence Cappitech, the survey found that 99% of respondents indicate having reporting obligations in at least two jurisdictions.
  • S&P Global Market Intelligence is a division of S&P Global (NYSE: SPGI).

ESMA to withdraw the recognition decisions of six Indian CCPs

Retrieved on: 
Friday, November 11, 2022

ESMA to withdraw the recognition decisions of six Indian CCPs

Key Points: 
  • ESMA to withdraw the recognition decisions of six Indian CCPs
    The European Securities and Markets Authority (ESMA), the EUs financial markets regulator and supervisor, today announces that six central counterparties (CCPs) established in India will have their recognition decisions withdrawn in accordance with the European Market Infrastructure Regulation (EMIR).
  • ESMA had to tier and review the recognition of all third country CCPs (TC-CCPs) that had been recognised prior to 21 September 2020, in accordance with EMIR (Article 89(3c)).
  • As a result, ESMA concludes that these TC-CCPs cannot continue to be recognised in the European Union under the currently applicable EMIR regime.
  • To mitigate the adverse impacts on EU market participants, ESMA will defer the application of the withdrawal decisions until 30 April 2023.

Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022

Retrieved on: 
Tuesday, October 18, 2022

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the companys upcoming new data from its HIV research and development programs to be presented at the 30th International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2022) in Glasgow, Scotland and virtually from October 23-26, 2022.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced the companys upcoming new data from its HIV research and development programs to be presented at the 30th International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2022) in Glasgow, Scotland and virtually from October 23-26, 2022.
  • The data presented at HIV Glasgow reflect the latest progress in our research and development programs and underscore Gileads commitment to driving transformational innovation in HIV research.
  • Biktarvy, Sunlenca, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter ( @Gilead Sciences ) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

Retrieved on: 
Monday, September 12, 2022

Kidney transplant candidates are classified as highly sensitized if they have a broad and intense range of pre-formed antibodies against almost all donororgans.

Key Points: 
  • Kidney transplant candidates are classified as highly sensitized if they have a broad and intense range of pre-formed antibodies against almost all donororgans.
  • It is fantastic to see that the SMC has followed the direction of England and Wales to offer certain highly sensitized patients the opportunity of a life-altering transplant.
  • "We are thrilled that the SMC has recommended Idefirixas the first licensed therapy for highly sensitized kidney patients in Scotland.
  • Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.

Hansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients

Retrieved on: 
Monday, July 11, 2022

We can now happily report that our patient was the first to receive an Idefirix -enabled kidney transplant as part of this important study.

Key Points: 
  • We can now happily report that our patient was the first to receive an Idefirix -enabled kidney transplant as part of this important study.
  • This open-label Phase 3 study will enroll 50 highly sensitized adult kidney transplant patients with positive crossmatch against an available deceased donor to confirm the long-term efficacy and safety of Idefirix.
  • The PAES will enrol patients across multiple countries and centers in Europe and the study will include 50 highly sensitized and crossmatch positive patients to be treated with Idefirix.
  • Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.